Highmark
Regional Blues insurer whose 2022 decision to cover prescription digital therapeutics was one of the first and most visible large-plan moves to do so — a benchmark in the pediatric reimbursement debate.
What They Do
Highmark operates commercial, employer, and government-sponsored health insurance products across multiple states. It is relevant to PHD not because it is pediatric-native, but because its 2022 move to cover prescription digital therapeutics became one of the clearest examples of how sparse and fragmented payer adoption remained for products like EndeavorRx.
Competitive Position
Highmark is relevant as a payer signal — one of the few large health plans to adopt prescription digital therapeutic coverage. Its behavior establishes a benchmark for what progressive payer adoption looks like and how slowly coverage norms spread from early movers to the broader market.
Funding Rounds
No funding rounds on record for this company.